English
Chinese
Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting
No Items In Cart
FluroTec®活塞
概述
产品属性
*非FluroTec尺寸可用于不同的配置
Packaging Options
FluroTec® and Westar® are registered trademarks of West Pharmaceutical Services, Inc. in the United States and in other jurisdictions.
FluroTec® technology is licensed from Daikyo Seiko, Ltd.
FluroTec® technology is licensed from Daikyo Seiko, Ltd.
Related Blogs
四月 02, 2021
FluroTec™ Barrier Films – Protecting Your Biologics
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
四月 19, 2021
NovaPure® Components Answer Your Concerns over Particulates in Biologics
An enormous growth trend is being observed in the market for biologic drugs; they are being employed ever more frequently as treatments for chronic issues such as cancer and autoimmune diseases. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
三月 16, 2021
Addressing the Challenges in Research for Biologics
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
四月 02, 2021
FluroTec™ Barrier Films – Protecting Your Biologics
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
四月 19, 2021
NovaPure® Components Answer Your Concerns over Particulates in Biologics
An enormous growth trend is being observed in the market for biologic drugs; they are being employed ever more frequently as treatments for chronic issues such as cancer and autoimmune diseases. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
三月 16, 2021
Addressing the Challenges in Research for Biologics
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
